EU regulator backs use of Novo's Wegovy for obesity-related heart condition
This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits. The agency has also backed use of Wegovy to lower major heart risks and strokes in overweight or obese adults without diabetes.
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
Based on the results of the trial, drugmaker Novo Nordisk has asked U.S. regulators to expand use of the medication for ...
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
15h
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo ...
Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...
Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback